Semaglutide as a promising treatment for metabolic dysfunction‑associated steatotic liver disease
Open Access
- 31 March 2025
- journal article
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 94 (1) , e1219
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder globally, and if left untreated, it may progress to liver cirrhosis and even hepatocellular carcinoma. As of 2024, the European Association for the Study of the Liver Guidelines have recommended resmetirom as the only pharmacological treatment for adults with non-cirrhotic MASLD who have significant fibrosis (stage ≥2). However, lifestyle interventions and management of comorbidities, such as type 2 diabetes and obesity, remain the cornerstone of treatment. Glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown emerging promise in treating MASLD. Notably, the Phase III ESSENCE trial, presented in late 2024, demonstrated semaglutide's potential in improving liver fibrosis, confirmed through histological evaluation, marking a possible breakthrough for MASLD management. This review aims to synthesise current evidence on the efficacy of semaglutide in treating MASLD, highlighting its potential to fill a significant gap in the therapeutic options available for this growing global health concern.Keywords
This publication has 20 references indexed in Scilit:
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialThe Lancet Gastroenterology & Hepatology, 2023
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot studyJGH Open, 2022
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialJournal of Hepatology, 2022
- GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitisActa Pharmacologica Sinica, 2021
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2021
- Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisHepatology, 2019
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014